This study is testing a lower dose of Capecitabine, a chemotherapy pill, for women with advanced breast cancer that has spread (metastatic breast cancer). It's for those aged 60 or older, or younger patients who are frail and might have more difficulty with other treatments. To join, your breast cancer must be HER2-negative, meaning it doesn't have too much of a protein called HER2. The main goal is to see how many patients respond to the treatment, which will be checked over about 12 weeks. This study is currently recruiting 40 participants.

Study design

This is a Phase II, single-arm study, meaning all 40 participants will receive the study drug, Capecitabine. It is not specified if the study is open-label or blinded.

What's involved

You would take Capecitabine pills once daily by mouth. The study will continue until your disease progresses or if you experience unacceptable side effects.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, objective response rate, will be evaluated from baseline up to 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.